Opioid Dependence and the Future of Treatment: Buprenorphine in the VA



May 14, 2013

Opioid Dependence and the Future of Treatment: Buprenorphine in the VA
 
Adam J. Gordon, MD MPH FACP FASAM
Associate Professor of Medicine and
Advisory Dean
University of Pittsburgh School of Medicine
VA Pittsburgh Healthcare System
Pittsburgh, PA
 
 
Opioid dependence deleteriously influences the health of many individuals, including an increasing number of United States military veterans.  Increasing identification and treatment of veterans with substance use disorders are national priorities.

The United States Veterans Health Administration (VHA) recently issued guidelines regarding screening, assessment, and treatment of patients with substance use disorders, including use of office and clinic based buprenorphine for the  treatment of opioid dependence.  Since 2003, buprenorphine treatment was available in the VHA and recently, this treatment was mandated to be offered to all veterans with opioid addiction.

In this webinar, Dr. Gordon will describe the problem of opioid dependence among veteran populations, the historical context of passive and active VHA implementation efforts to increase the use of buprenorphine in the VHA, and facilitators and barriers to implementation of opioid agonist therapy in this large health care system.

View Dr. Gordon's presentation slides from this webinar.